0723 GMT - A late-stage trial showed that Roche's advanced breast cancer drug Itovebi not only delays disease progression but that these patients also live longer, Vontobel analyst Stefan Schneider says in a note. "Itovebi was already approved for first-line therapy on its primary endpoint last October and today's secondary endpoint reinforces that today," the analyst says. Vontobel leaves unchanged its 1.5 billion Swiss francs peak sales estimate for the drug in 2025.(helena.smolak@wsj.com)
(END) Dow Jones Newswires
January 28, 2025 02:24 ET (07:24 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。